The multifaceted biology of PCSK9

NG Seidah, A Prat - Endocrine reviews, 2022 - academic.oup.com
This article reviews the discovery of PCSK9, its structure–function characteristics, and its
presently known and proposed novel biological functions. The major critical function of …

[HTML][HTML] The potential use of simvastatin for cancer treatment: A review

JA Duarte, ALB de Barros, EA Leite - Biomedicine & Pharmacotherapy, 2021 - Elsevier
Statins, typically used to reduce lipid levels, have been rediscovered for exhibiting
anticancer activities. Among them, especially simvastatin may influence the proliferation …

PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of …

L Wang, S Li, H Luo, Q Lu, S Yu - Journal of Experimental & Clinical …, 2022 - Springer
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the ninth member of
the proprotein convertase family that regulates lipoprotein homeostasis and altered PCSK9 …

Beyond lipid-lowering: effects of statins on cardiovascular and cerebrovascular diseases and cancer

Y Morofuji, S Nakagawa, K Ujifuku, T Fujimoto… - Pharmaceuticals, 2022 - mdpi.com
The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, also known
as statins, are administered as first-line therapy for hypercholesterolemia, both as primary …

Cholesterol: An important actor on the cancer immune scene

H Halimi, S Farjadian - Frontiers in Immunology, 2022 - frontiersin.org
Based on the structural and signaling roles of cholesterol, which are necessary for immune
cell activity, high concentrations of cholesterol and its metabolites not only trigger malignant …

Finding new molecular targets of two copper (II)-hydrazone complexes on triple-negative breast cancer cells using mass-spectrometry-based quantitative proteomics

LM Balsa, MR Rodriguez, V Ferraresi-Curotto… - International journal of …, 2023 - mdpi.com
Breast cancer is the most common cancer in women, with a high incidence estimated to
reach 2.3 million by 2030. Triple-Negative Breast Cancer (TNBC) is the greatest invasive …

Decreasing trend of blood lipid profile in type 2 diabetes: Not a promising change in HDL-C, a serial cross-sectional study

A Yadegar, F Mohammadi, S Rabizadeh, A Meysamie… - Plos one, 2023 - journals.plos.org
Background The prevalence of dyslipidemia in patients with type 2 diabetes (T2D) has been
reported to be relatively high. The current study aimed to investigate the trend of serum lipid …

Contribution of serum lipids and cholesterol cellular metabolism in lung cancer development and progression

P Hartmann, DI Trufa, K Hohenberger, P Tausche… - Scientific Reports, 2023 - nature.com
Neoplasms of the lungs are the leading cause of cancer incidence and mortality worldwide.
Although immunotherapy has increased the overall survival of patients with lung cancer …

The evolving landscape of PCSK9 inhibition in cancer

PP Oza, K Kashfi - European journal of pharmacology, 2023 - Elsevier
Cancer is a disease with a significant global burden in terms of premature mortality, loss of
productivity, healthcare expenditures, and impact on mental health. Recent decades have …

Obesity programs macrophages to support cancer progression

A Singh, SS Mayengbam, H Yaduvanshi, MR Wani… - Cancer research, 2022 - AACR
Obesity induces multifactorial effects such as dyslipidemia, insulin resistance, and arterial
hypertension that influence the progression of many diseases. Obesity is associated with an …